G Nikolakis1,2, E von Stebut3. 1. Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau, Medizinische Hochschule Brandenburg Theodor Fontane und Fakultät für Gesundheitswissenschaften Brandenburg, Dessau, Deutschland. 2. European Hidradenitis Suppurativa Foundation e. V., Dessau, Deutschland. 3. Klinik für Dermatologie und Venerologie, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland. esther.von-stebut@uk-koeln.de.
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin folds, which requires more outpatient treatment alternatives. Although the disease was previously treated using surgery, new treatment modalities now allow the effective treatment of mild and moderate cases in an ambulatory care setting. AIM OF STUDY: Local and instrument-based therapies are presented and their efficacy and safety profiles are highlighted. MATERIALS AND METHODS: Clinical evidence for each therapeutic modality are presented and current treatment developments are analyzed based on the future treatment of HS patients in Germany. RESULTS: Effective treatments for outpatient care of HS patients include topical clindamycin, resorcinol, and intralesional corticosteroids. New devices such as LAight therapy (combining intense pulsed light [IPL] with radiofrequency) are available, which can be used as monotherapy or adjunct therapy in combination with systemic treatment and/or surgery for the management of HS. CONCLUSION: Evidence-based use of local treatments can provide more efficient outpatient and self-administered strategies, which improves the quality of life of HS patients, especially for patients with recurrent mild and moderate disease.
BACKGROUND:Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin folds, which requires more outpatient treatment alternatives. Although the disease was previously treated using surgery, new treatment modalities now allow the effective treatment of mild and moderate cases in an ambulatory care setting. AIM OF STUDY: Local and instrument-based therapies are presented and their efficacy and safety profiles are highlighted. MATERIALS AND METHODS: Clinical evidence for each therapeutic modality are presented and current treatment developments are analyzed based on the future treatment of HS patients in Germany. RESULTS: Effective treatments for outpatient care of HS patients include topical clindamycin, resorcinol, and intralesional corticosteroids. New devices such as LAight therapy (combining intense pulsed light [IPL] with radiofrequency) are available, which can be used as monotherapy or adjunct therapy in combination with systemic treatment and/or surgery for the management of HS. CONCLUSION: Evidence-based use of local treatments can provide more efficient outpatient and self-administered strategies, which improves the quality of life of HS patients, especially for patients with recurrent mild and moderate disease.
Authors: V Bettoli; M Manfredini; L Massoli; C Carillo; A Barozzi; G Amendolagine; G Ruina; D Musmeci; M Libanore; A Curtolo; L Mantovani; C Contini; G Pellacani; M Corazza Journal: J Eur Acad Dermatol Venereol Date: 2019-02-19 Impact factor: 6.166
Authors: Francisco Javier García-Martínez; Eva Vilarrasa Rull; Laura Salgado-Boquete; Antonio Martorell; Jose Carlos Pascual; Ángela Hernández-Martín; Catiana Silvente; Cristina Ciudad-Blanco; Eva Andrés Esteban; F Alfageme-Roldán Journal: J Dermatolog Treat Date: 2019-08-29 Impact factor: 3.359
Authors: Alexandre Docampo-Simón; Iván Beltrá-Picó; María José Sánchez-Pujol; Rosa Fuster-Ruiz-de-Apodaca; Juan Selva-Otaolaurruchi; Isabel Betlloch; José Carlos Pascual Journal: Dermatology Date: 2021-04-22 Impact factor: 5.366
Authors: Wayne Gulliver; Christos C Zouboulis; Errol Prens; Gregor B E Jemec; Thrasivoulos Tzellos Journal: Rev Endocr Metab Disord Date: 2016-09 Impact factor: 6.514